CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 231 enrolled
Drug / intervention
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00708422
NCT00708422Phase 4Completed
CompareCT.gov

Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan®

Alcon Research·interventional·Posted Jul 2, 2008·Updated Apr 23, 2012

In Brief

A Phase 4 clinical trial evaluating Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) for Glaucoma and Ocular Hypertension. Completed, enrolled 231 participants.

Detailed Summary

The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2, 2008
Enrollment StartJul 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18 years ago

Interventions

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

Latanoprost ophthalmic solution 0.005% (XALATAN®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.